--- title: "Obsidian Therapeutics To Merge With Galera In Reverse Merger" type: "News" locale: "en" url: "https://longbridge.com/en/news/282795257.md" description: "RTW Biotech Opportunities Ltd announced that Galera Therapeutics will merge with Obsidian Therapeutics in a reverse merger. The all-stock deal includes a $350 million private placement financing. The new entity will trade on Nasdaq under the ticker \"OBX\" starting Q3 2026. Obsidian focuses on cell therapies for solid tumors, with its lead candidate OBX-115 in Phase 2 trials for melanoma and Phase 1 for lung cancer. RTW's shares rose 3.38% to $2.14, while Galera's shares surged 88.10% to $0.0790." datetime: "2026-04-15T06:40:54.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/282795257.md) - [en](https://longbridge.com/en/news/282795257.md) - [zh-HK](https://longbridge.com/zh-HK/news/282795257.md) --- # Obsidian Therapeutics To Merge With Galera In Reverse Merger Add as your preferred news source on Google Add Now RTW Biotech Opportunities Ltd (RTW.L), on Wednesday, noted that Galera Therapeutics, Inc. (GRTX) has entered into a definitive agreement to merge with private portfolio company Obsidian Therapeutics Inc. in a reverse merger transaction. The all-stock merger will be conducted alongside a $350 million private placement financing, in which RTW Biotech Opportunities is participating. The combined company is expected to begin trading on the Nasdaq under the ticker "OBX" in the third quarter of 2026. Obsidian, a clinical-stage biopharmaceutical company focused on cell therapies for solid tumors, is advancing its lead candidate OBX-115 in Phase 2 trials for advanced melanoma and Phase 1 trials for non-small cell lung cancer. As of March 31, 2026, Obsidian represented approximately 0.3% of RTW Biotech Opportunities' net asset value. On Tuesday, RTW Biotech Opportunities closed trading 3.38% higher at $2.1400 on the London Stock Exchange. On Tuesday, Galera Therapeutics closed trading 88.10% higher at $0.0790 on the OTC. For comments and feedback contact: editorial@rttnews.com Business News ### Related Stocks - [GRTX.US](https://longbridge.com/en/quote/GRTX.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) ## Related News & Research - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md) - [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md) - [BioMarin's drug shows significant growth gains in children in late-stage trial](https://longbridge.com/en/news/287121584.md) - [](https://longbridge.com/en/news/286807703.md) - [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)